| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 23 | 2026 | 999 | 2.990 |
Why?
|
| Heart Failure | 18 | 2026 | 2315 | 1.680 |
Why?
|
| Lung Transplantation | 10 | 2024 | 357 | 1.520 |
Why?
|
| Extracorporeal Membrane Oxygenation | 10 | 2022 | 675 | 1.380 |
Why?
|
| Heart Transplantation | 7 | 2024 | 833 | 1.300 |
Why?
|
| Minimally Invasive Surgical Procedures | 3 | 2024 | 201 | 0.860 |
Why?
|
| Catheterization, Central Venous | 2 | 2012 | 141 | 0.650 |
Why?
|
| Hepatitis C | 2 | 2017 | 390 | 0.640 |
Why?
|
| Device Removal | 1 | 2020 | 223 | 0.570 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2024 | 184 | 0.550 |
Why?
|
| Uridine Monophosphate | 1 | 2017 | 8 | 0.540 |
Why?
|
| Fluorenes | 1 | 2017 | 7 | 0.540 |
Why?
|
| Benzimidazoles | 1 | 2017 | 155 | 0.490 |
Why?
|
| Hepacivirus | 1 | 2017 | 273 | 0.460 |
Why?
|
| Preoperative Care | 1 | 2017 | 357 | 0.450 |
Why?
|
| Tissue and Organ Procurement | 3 | 2015 | 253 | 0.450 |
Why?
|
| Shock, Cardiogenic | 3 | 2021 | 174 | 0.440 |
Why?
|
| Resource Allocation | 1 | 2014 | 52 | 0.430 |
Why?
|
| Middle Aged | 31 | 2026 | 28911 | 0.420 |
Why?
|
| Ventricular Dysfunction, Right | 3 | 2024 | 80 | 0.420 |
Why?
|
| Tissue Donors | 6 | 2020 | 502 | 0.400 |
Why?
|
| Polytetrafluoroethylene | 2 | 2019 | 62 | 0.380 |
Why?
|
| Upper Extremity Deep Vein Thrombosis | 1 | 2012 | 3 | 0.380 |
Why?
|
| Retrospective Studies | 23 | 2026 | 17703 | 0.370 |
Why?
|
| Takayasu Arteritis | 1 | 2012 | 11 | 0.360 |
Why?
|
| Peritoneal Cavity | 1 | 2011 | 20 | 0.360 |
Why?
|
| Antiviral Agents | 1 | 2017 | 813 | 0.360 |
Why?
|
| Reoperation | 3 | 2024 | 844 | 0.360 |
Why?
|
| Anastomotic Leak | 1 | 2012 | 35 | 0.360 |
Why?
|
| Lung Diseases | 2 | 2019 | 401 | 0.350 |
Why?
|
| Embolism | 1 | 2011 | 39 | 0.350 |
Why?
|
| Ventricular Remodeling | 1 | 2012 | 155 | 0.350 |
Why?
|
| Ventricular Function, Right | 1 | 2012 | 126 | 0.340 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2011 | 76 | 0.340 |
Why?
|
| Humans | 55 | 2026 | 131967 | 0.330 |
Why?
|
| Adult | 23 | 2026 | 31734 | 0.320 |
Why?
|
| Thrombosis | 3 | 2022 | 495 | 0.310 |
Why?
|
| Female | 34 | 2026 | 71316 | 0.300 |
Why?
|
| Heart Atria | 1 | 2011 | 338 | 0.290 |
Why?
|
| Male | 34 | 2026 | 65357 | 0.290 |
Why?
|
| Ventricular Function, Left | 2 | 2024 | 542 | 0.290 |
Why?
|
| Aged | 17 | 2026 | 21279 | 0.260 |
Why?
|
| Survival Rate | 5 | 2019 | 2154 | 0.260 |
Why?
|
| Aorta, Thoracic | 1 | 2012 | 537 | 0.260 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2021 | 359 | 0.250 |
Why?
|
| Vascular Surgical Procedures | 1 | 2012 | 540 | 0.250 |
Why?
|
| Ischemia | 2 | 2024 | 355 | 0.250 |
Why?
|
| Staphylococcal Infections | 1 | 2011 | 569 | 0.250 |
Why?
|
| Follow-Up Studies | 6 | 2024 | 5298 | 0.250 |
Why?
|
| ADAM10 Protein | 1 | 2026 | 13 | 0.240 |
Why?
|
| Pulmonary Artery | 2 | 2024 | 441 | 0.240 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2026 | 59 | 0.230 |
Why?
|
| Treatment Outcome | 14 | 2024 | 13011 | 0.230 |
Why?
|
| Endostatins | 1 | 2025 | 10 | 0.230 |
Why?
|
| Thromboembolism | 1 | 2026 | 92 | 0.230 |
Why?
|
| Ohio | 3 | 2014 | 88 | 0.230 |
Why?
|
| Vascular Resistance | 2 | 2024 | 182 | 0.220 |
Why?
|
| Graft Rejection | 2 | 2019 | 562 | 0.220 |
Why?
|
| Cadherins | 1 | 2026 | 178 | 0.220 |
Why?
|
| Lung | 4 | 2024 | 1571 | 0.220 |
Why?
|
| Cystatin C | 1 | 2025 | 71 | 0.220 |
Why?
|
| Delirium | 1 | 2025 | 66 | 0.210 |
Why?
|
| Antigens, CD | 1 | 2026 | 418 | 0.210 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2026 | 231 | 0.200 |
Why?
|
| Cystic Fibrosis | 2 | 2019 | 267 | 0.200 |
Why?
|
| Prosthesis-Related Infections | 1 | 2025 | 194 | 0.200 |
Why?
|
| Heparin | 3 | 2013 | 206 | 0.190 |
Why?
|
| Prosthesis Implantation | 1 | 2024 | 148 | 0.190 |
Why?
|
| Subclavian Vein | 2 | 2012 | 19 | 0.190 |
Why?
|
| Catheterization | 3 | 2012 | 234 | 0.190 |
Why?
|
| Anticoagulants | 4 | 2022 | 597 | 0.190 |
Why?
|
| Mitral Valve | 1 | 2024 | 250 | 0.190 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2023 | 105 | 0.180 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2024 | 440 | 0.170 |
Why?
|
| Sepsis | 1 | 2026 | 501 | 0.170 |
Why?
|
| Hyponatremia | 1 | 2022 | 74 | 0.170 |
Why?
|
| Postoperative Complications | 5 | 2025 | 3135 | 0.170 |
Why?
|
| Pancreatic Neoplasms | 6 | 2005 | 732 | 0.170 |
Why?
|
| Machine Learning | 1 | 2024 | 375 | 0.160 |
Why?
|
| Tracheostomy | 2 | 2023 | 215 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2025 | 2123 | 0.160 |
Why?
|
| Renal Replacement Therapy | 1 | 2021 | 161 | 0.150 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2024 | 1173 | 0.150 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 3 | 2005 | 39 | 0.150 |
Why?
|
| Mitochondria | 1 | 2024 | 766 | 0.150 |
Why?
|
| Hemorrhage | 2 | 2019 | 499 | 0.140 |
Why?
|
| Medical Overuse | 1 | 2018 | 24 | 0.140 |
Why?
|
| Renal Insufficiency | 1 | 2021 | 252 | 0.140 |
Why?
|
| Pseudomonas Infections | 1 | 2019 | 117 | 0.140 |
Why?
|
| Kidney | 1 | 2025 | 1304 | 0.140 |
Why?
|
| Membrane Proteins | 1 | 2026 | 1612 | 0.140 |
Why?
|
| Acute Lung Injury | 1 | 2018 | 67 | 0.140 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2019 | 153 | 0.140 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2019 | 175 | 0.130 |
Why?
|
| Incidence | 4 | 2024 | 3352 | 0.130 |
Why?
|
| Sofosbuvir | 1 | 2017 | 20 | 0.130 |
Why?
|
| Allografts | 1 | 2018 | 215 | 0.130 |
Why?
|
| Acute Kidney Injury | 1 | 2025 | 690 | 0.130 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 222 | 0.130 |
Why?
|
| Time Factors | 6 | 2024 | 6285 | 0.130 |
Why?
|
| Echocardiography | 3 | 2011 | 1138 | 0.120 |
Why?
|
| Graft Survival | 3 | 2020 | 466 | 0.120 |
Why?
|
| Stroke | 1 | 2024 | 1049 | 0.120 |
Why?
|
| Blood Transfusion | 1 | 2018 | 291 | 0.120 |
Why?
|
| Thiophenes | 4 | 2000 | 68 | 0.120 |
Why?
|
| Phenylalanine | 4 | 2000 | 126 | 0.120 |
Why?
|
| Risk Factors | 7 | 2026 | 10998 | 0.120 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 734 | 0.120 |
Why?
|
| Equipment Design | 2 | 2021 | 557 | 0.120 |
Why?
|
| Metalloendopeptidases | 3 | 2000 | 104 | 0.110 |
Why?
|
| Pulmonary Heart Disease | 1 | 2014 | 4 | 0.110 |
Why?
|
| Prognosis | 4 | 2021 | 4961 | 0.110 |
Why?
|
| Bacteria | 1 | 2018 | 541 | 0.110 |
Why?
|
| Compartment Syndromes | 1 | 2014 | 33 | 0.110 |
Why?
|
| Fatal Outcome | 2 | 2013 | 364 | 0.110 |
Why?
|
| Death | 1 | 2015 | 77 | 0.100 |
Why?
|
| Extremities | 1 | 2014 | 77 | 0.100 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2014 | 157 | 0.100 |
Why?
|
| Young Adult | 5 | 2019 | 10108 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 1078 | 0.100 |
Why?
|
| Brain | 1 | 2025 | 3247 | 0.090 |
Why?
|
| Hospitals, University | 1 | 2012 | 103 | 0.090 |
Why?
|
| Axillary Artery | 1 | 2012 | 30 | 0.090 |
Why?
|
| Donor Selection | 1 | 2013 | 58 | 0.090 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2012 | 34 | 0.090 |
Why?
|
| Drug Overdose | 1 | 2013 | 72 | 0.090 |
Why?
|
| Jugular Veins | 1 | 2012 | 74 | 0.090 |
Why?
|
| Aneurysm, Ruptured | 1 | 2011 | 34 | 0.090 |
Why?
|
| Coronary Aneurysm | 1 | 2011 | 35 | 0.090 |
Why?
|
| Matrix Metalloproteinase 2 | 5 | 2005 | 88 | 0.090 |
Why?
|
| Catheters, Indwelling | 1 | 2012 | 150 | 0.090 |
Why?
|
| Equipment Failure | 1 | 2011 | 131 | 0.090 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2011 | 51 | 0.090 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2012 | 140 | 0.080 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 1406 | 0.080 |
Why?
|
| Treatment Failure | 1 | 2012 | 353 | 0.080 |
Why?
|
| Adenocarcinoma | 3 | 2005 | 1001 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 2578 | 0.080 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2012 | 273 | 0.080 |
Why?
|
| End Stage Liver Disease | 1 | 2012 | 191 | 0.080 |
Why?
|
| Liver Function Tests | 1 | 2010 | 97 | 0.080 |
Why?
|
| Fibroma | 1 | 2010 | 29 | 0.080 |
Why?
|
| Hospitals | 2 | 2023 | 445 | 0.080 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 242 | 0.080 |
Why?
|
| Pulmonary Embolism | 1 | 2012 | 191 | 0.080 |
Why?
|
| Risk Assessment | 4 | 2024 | 3708 | 0.080 |
Why?
|
| Gelatinases | 2 | 1999 | 16 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2012 | 397 | 0.070 |
Why?
|
| Heart Neoplasms | 1 | 2010 | 107 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 1916 | 0.070 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2012 | 474 | 0.070 |
Why?
|
| Protease Inhibitors | 2 | 1999 | 95 | 0.070 |
Why?
|
| Transfection | 3 | 2005 | 960 | 0.070 |
Why?
|
| Stroke Volume | 1 | 2010 | 532 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 2012 | 463 | 0.070 |
Why?
|
| Mortality | 2 | 2019 | 261 | 0.060 |
Why?
|
| Biomarkers | 2 | 2026 | 3415 | 0.060 |
Why?
|
| DNA, Antisense | 1 | 2005 | 8 | 0.060 |
Why?
|
| Preoperative Period | 1 | 2025 | 92 | 0.060 |
Why?
|
| Atrophy | 1 | 2025 | 251 | 0.050 |
Why?
|
| Neoplasm Transplantation | 5 | 2005 | 361 | 0.050 |
Why?
|
| Heart Arrest, Induced | 1 | 2024 | 74 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2024 | 130 | 0.050 |
Why?
|
| Organ Size | 1 | 2025 | 437 | 0.050 |
Why?
|
| ROC Curve | 1 | 2026 | 622 | 0.050 |
Why?
|
| Gene Expression | 3 | 2005 | 1503 | 0.050 |
Why?
|
| Liver Transplantation | 1 | 2012 | 1133 | 0.050 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 2 | 2000 | 17 | 0.050 |
Why?
|
| Mice, Nude | 5 | 2005 | 714 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2010 | 904 | 0.050 |
Why?
|
| Hypothermia, Induced | 1 | 2024 | 175 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2025 | 6522 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2010 | 1002 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2019 | 1239 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 5 | 2002 | 989 | 0.050 |
Why?
|
| Neuroimaging | 1 | 2025 | 406 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1519 | 0.040 |
Why?
|
| Immunohistochemistry | 4 | 2010 | 1610 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2002 | 234 | 0.040 |
Why?
|
| Sex Factors | 1 | 2024 | 1352 | 0.040 |
Why?
|
| Mean Platelet Volume | 1 | 2019 | 4 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 1224 | 0.040 |
Why?
|
| I-kappa B Proteins | 1 | 1999 | 37 | 0.040 |
Why?
|
| Macrophages, Peritoneal | 1 | 1999 | 36 | 0.040 |
Why?
|
| Polymyxins | 1 | 2019 | 15 | 0.040 |
Why?
|
| Collagenases | 1 | 1999 | 16 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2002 | 710 | 0.040 |
Why?
|
| Shock, Hemorrhagic | 1 | 1999 | 52 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2022 | 1522 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2023 | 1076 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2022 | 770 | 0.030 |
Why?
|
| Shock, Septic | 1 | 1999 | 149 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2018 | 335 | 0.030 |
Why?
|
| NF-kappa B | 1 | 1999 | 450 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 3095 | 0.030 |
Why?
|
| Blotting, Western | 3 | 2005 | 1018 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2019 | 379 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2018 | 501 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 1598 | 0.030 |
Why?
|
| Organ Preservation | 1 | 2015 | 61 | 0.030 |
Why?
|
| Texas | 1 | 2022 | 3629 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 1626 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 192 | 0.030 |
Why?
|
| Animals | 9 | 2012 | 34460 | 0.020 |
Why?
|
| Waiting Lists | 1 | 2015 | 242 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2000 | 1357 | 0.020 |
Why?
|
| Reperfusion | 1 | 2012 | 26 | 0.020 |
Why?
|
| Mice | 7 | 2005 | 18504 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2019 | 3453 | 0.020 |
Why?
|
| Acute Disease | 1 | 2014 | 1153 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 741 | 0.020 |
Why?
|
| Perfusion | 1 | 2012 | 211 | 0.020 |
Why?
|
| Quality of Life | 1 | 2021 | 2116 | 0.020 |
Why?
|
| Endocardial Fibroelastosis | 1 | 2010 | 10 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 2 | 2005 | 646 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 2010 | 130 | 0.020 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2010 | 84 | 0.020 |
Why?
|
| Chest Pain | 1 | 2010 | 129 | 0.020 |
Why?
|
| Swine | 1 | 2012 | 1191 | 0.020 |
Why?
|
| Dyspnea | 1 | 2010 | 161 | 0.020 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2010 | 252 | 0.020 |
Why?
|
| Oxygen | 1 | 2012 | 553 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2010 | 457 | 0.020 |
Why?
|
| Adolescent | 2 | 2019 | 21008 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 2 | 2000 | 1020 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 4684 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 2869 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2010 | 984 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 2002 | 2573 | 0.010 |
Why?
|
| Plasmids | 1 | 2005 | 455 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2010 | 1215 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2002 | 122 | 0.010 |
Why?
|
| Coloring Agents | 1 | 2002 | 72 | 0.010 |
Why?
|
| Pancreas | 1 | 2002 | 218 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 2000 | 56 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 731 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2000 | 272 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2000 | 216 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2000 | 82 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 2000 | 205 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2000 | 432 | 0.010 |
Why?
|
| Matrix Metalloproteinases, Membrane-Associated | 1 | 1999 | 3 | 0.010 |
Why?
|
| Survival | 1 | 1999 | 15 | 0.010 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 1999 | 33 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1999 | 148 | 0.010 |
Why?
|
| Reference Values | 1 | 2000 | 692 | 0.010 |
Why?
|
| Cytosol | 1 | 1999 | 140 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2000 | 792 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 1999 | 139 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1999 | 590 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2005 | 2483 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 1999 | 302 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 3708 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1999 | 567 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1999 | 643 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1999 | 1146 | 0.010 |
Why?
|
| Body Weight | 1 | 2000 | 990 | 0.010 |
Why?
|
| Apoptosis | 1 | 2002 | 1860 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 1398 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1999 | 2963 | 0.010 |
Why?
|
| Rats | 1 | 1999 | 3462 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2002 | 1394 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 1999 | 1964 | 0.010 |
Why?
|
| Signal Transduction | 1 | 1999 | 4693 | 0.000 |
Why?
|